NYSEAMERICAN:KAPA Kairos Pharma (KAPA) Stock Price, News & Analysis $0.55 0.00 (0.00%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$0.53 -0.02 (-2.75%) As of 05/22/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Kairos Pharma Stock (NYSEAMERICAN:KAPA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kairos Pharma alerts:Sign Up Key Stats Today's Range$0.52▼$0.5550-Day Range$0.46▼$0.6852-Week Range$0.40▼$2.11Volume136,268 shsAverage Volume186,702 shsMarket Capitalization$11.67 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications. Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics. The company collaborates with academic institutions and patient advocacy groups to advance its programs through clinical milestones and facilitate patient access. By concentrating on precision modulation of the translational machinery, Kairos Pharma aims to address diseases with high unmet medical need and no currently approved treatments. Governed by an experienced leadership team with backgrounds in drug development, regulatory affairs and commercial strategy, Kairos Pharma maintains research operations in the United States and Europe. The company continues to forge strategic partnerships and secure financing to support its development programs and expand its pipeline. With a science‐driven approach and commitment to rare disease communities, Kairos Pharma is positioned to deliver innovative therapies to patients worldwide.AI Generated. May Contain Errors. Read More Kairos Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreKAPA MarketRank™: Kairos Pharma scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKairos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialKairos Pharma has a consensus price target of $9.00, representing about 1,551.4% upside from its current price of $0.55.Amount of Analyst CoverageKairos Pharma has received no research coverage in the past 90 days.Read more about Kairos Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kairos Pharma are expected to decrease in the coming year, from ($0.37) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kairos Pharma is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kairos Pharma is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKairos Pharma has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of Kairos Pharma has been sold short.Short Interest Ratio / Days to CoverKairos Pharma has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kairos Pharma has recently decreased by 14.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKairos Pharma does not currently pay a dividend.Dividend GrowthKairos Pharma does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.48 News SentimentKairos Pharma has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kairos Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for KAPA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kairos Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders39.60% of the stock of Kairos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKairos Pharma has minimal institutional ownership at this time.Read more about Kairos Pharma's insider trading history. Receive KAPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kairos Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KAPA Stock News HeadlinesKairos Pharma Highlights Clinical Programs at LD MicroMay 18, 2026 | tipranks.comKairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual FilingsMay 8, 2026 | businesswire.comThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off. | Weiss Ratings (Ad)KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law FirmApril 28, 2026 | globenewswire.comKairos Pharma (KAPA) price target decreased by 14.29% to 9.18April 15, 2026 | msn.comKairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPAApril 12, 2026 | businesswire.comRosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPAApril 11, 2026 | businesswire.comKairos Pharma (KAPA) price target increased by 26.00% to 10.71April 9, 2026 | msn.comSee More Headlines KAPA Stock Analysis - Frequently Asked Questions How have KAPA shares performed this year? Kairos Pharma's stock was trading at $0.71 at the beginning of the year. Since then, KAPA shares have decreased by 23.2% and is now trading at $0.5450. How were Kairos Pharma's earnings last quarter? Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) posted its earnings results on Wednesday, May, 13th. The company reported ($0.08) earnings per share for the quarter. How do I buy shares of Kairos Pharma? Shares of KAPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today5/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KAPA's financial health is in the Yellow zone, according to TradeSmith. KAPA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:KAPA CIK1962011 WebN/A Phone(818) 404-5541FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Kairos Pharma$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+1,551.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.26% Return on Assets-86.43% Debt Debt-to-Equity RatioN/A Current Ratio10.31 Quick Ratio10.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book2.18Miscellaneous Outstanding Shares21,410,000Free Float12,932,000Market Cap$11.67 million OptionableN/A Beta1.51 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSEAMERICAN:KAPA) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kairos Pharma, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kairos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
